Literature DB >> 21195051

Activated expression of cardiac adenylyl cyclase 6 reduces dilation and dysfunction of the pressure-overloaded heart.

Yasuo Sugano1, N Chin Lai, Mei Hua Gao, Amy L Firth, Jason X-J Yuan, Wilbur Y W Lew, H Kirk Hammond.   

Abstract

BACKGROUND AND
OBJECTIVE: Cardiac-directed adenylyl cyclase 6 (AC6) expression attenuates left ventricular (LV) hypertrophy and dysfunction in cardiomyopathy, but its effects in the pressure-overloaded heart are unknown.
METHODS: Mice with cardiac-directed and regulated expression of AC6 underwent transaortic constriction (TAC) to induce LV pressure overload. Ten days prior to TAC, and for the duration of the 4 week study, cardiac myocyte AC6 expression was activated in one group (AC-On) but not the other (AC-Off). Multiple measures of LV systolic and diastolic function were obtained 4 weeks after TAC, and LV samples assessed for alterations in Ca2+ signaling.
RESULTS: LV contractility, as reflected in the end-systolic pressure-volume relationship (Emax), was increased (p=0.01) by activation of AC6 expression. In addition, diastolic function was improved (p<0.05) and LV dilation was reduced (p<0.05). LV samples from AC-On mice showed reduced protein expression of sodium/calcium exchanger (NCX1) (p<0.05), protein phosphatase 1 (PP1) (p<0.01), and increased phosphorylation of phospholamban (PLN) at Ser16 (p<0.05). Finally, sarcoplasmic reticulum (SR) Ca2+ content was increased in cardiac myocytes isolated from AC-On mice (p<0.05).
CONCLUSIONS: Activation of cardiac AC6 expression improves function of the pressure-overloaded and failing heart. The predominant mechanism for this favorable adaptation is improved Ca2+ handling, a consequence of increased PLN phosphorylation, reduced NCX1, reduced PP1 expression, and increased SR Ca2+ content.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21195051      PMCID: PMC3219303          DOI: 10.1016/j.bbrc.2010.12.113

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  Type 1 phosphatase, a negative regulator of cardiac function.

Authors:  Andrew N Carr; Albrecht G Schmidt; Yoichi Suzuki; Federica del Monte; Yoji Sato; Carita Lanner; Kristine Breeden; Shao-Ling Jing; Patrick B Allen; Paul Greengard; Atsuko Yatani; Brian D Hoit; Ingrid L Grupp; Roger J Hajjar; Anna A DePaoli-Roach; Evangelia G Kranias
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

2.  Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload.

Authors:  Aziz Guellich; Shumin Gao; Chull Hong; Lin Yan; Thomas E Wagner; Sunil K Dhar; Bijan Ghaleh; Luc Hittinger; Kosaku Iwatsubo; Yoshihiro Ishikawa; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

3.  Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation.

Authors:  P Bokník; M Fockenbrock; S Herzig; J Knapp; B Linck; H Lüss; F U Müller; T Müller; W Schmitz; F Schröder; J Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-09       Impact factor: 3.000

4.  Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a.

Authors:  C L Antos; N Frey; S O Marx; S Reiken; M Gaburjakova; J A Richardson; A R Marks; E N Olson
Journal:  Circ Res       Date:  2001-11-23       Impact factor: 17.367

5.  Adenylyl cyclase increases survival in cardiomyopathy.

Authors:  David M Roth; Hamed Bayat; Jeffrey D Drumm; Mei Hua Gao; James S Swaney; Aziz Ander; H Kirk Hammond
Journal:  Circulation       Date:  2002-04-23       Impact factor: 29.690

6.  Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban.

Authors:  L K MacDougall; L R Jones; P Cohen
Journal:  Eur J Biochem       Date:  1991-03-28

7.  Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy.

Authors:  Tong Tang; Mei Hua Gao; David M Roth; Tracy Guo; H Kirk Hammond
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-07-08       Impact factor: 4.733

8.  Adenylyl cyclase type VI gene transfer reduces phospholamban expression in cardiac myocytes via activating transcription factor 3.

Authors:  Mei Hua Gao; Tong Tang; Tracy Guo; Shu Qiang Sun; James R Feramisco; H Kirk Hammond
Journal:  J Biol Chem       Date:  2004-07-01       Impact factor: 5.157

9.  Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function.

Authors:  Mei Hua Gao; Hamed Bayat; David M Roth; Jin Yao Zhou; Jeffrey Drumm; John Burhan; H Kirk Hammond
Journal:  Cardiovasc Res       Date:  2002-11       Impact factor: 10.787

10.  Partial inhibition of sodium/calcium exchange restores cellular calcium handling in canine heart failure.

Authors:  Ion A Hobai; Christoph Maack; Brian O'Rourke
Journal:  Circ Res       Date:  2004-06-24       Impact factor: 17.367

View more
  7 in total

Review 1.  Prospects for gene transfer for clinical heart failure.

Authors:  T Tang; M H Gao; H Kirk Hammond
Journal:  Gene Ther       Date:  2012-04-26       Impact factor: 5.250

Review 2.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

3.  Recovery of rhythmic activity in a central pattern generator: analysis of the role of neuromodulator and activity-dependent mechanisms.

Authors:  Yili Zhang; Jorge Golowasch
Journal:  J Comput Neurosci       Date:  2011-05-15       Impact factor: 1.621

4.  Response to Letter to the Editor on "Does Vidarabine Mediate Cardioprotection via Inhibition of AC5?".

Authors:  Claudio A Bravo; Dorothy E Vatner; Stephen F Vatner
Journal:  J Pharmacol Exp Ther       Date:  2016-08       Impact factor: 4.030

Review 5.  A kinase-anchoring proteins and adenylyl cyclase in cardiovascular physiology and pathology.

Authors:  Riad Efendiev; Carmen W Dessauer
Journal:  J Cardiovasc Pharmacol       Date:  2011-10       Impact factor: 3.105

6.  miR-182 Modulates Myocardial Hypertrophic Response Induced by Angiogenesis in Heart.

Authors:  Na Li; Cheol Hwangbo; Irina M Jaba; Jiasheng Zhang; Irinna Papangeli; Jinah Han; Nicole Mikush; Bruno Larrivée; Anne Eichmann; Hyung J Chun; Lawrence H Young; Daniela Tirziu
Journal:  Sci Rep       Date:  2016-02-18       Impact factor: 4.379

Review 7.  Protein tyrosine phosphatases in cardiac physiology and pathophysiology.

Authors:  Fallou Wade; Karim Belhaj; Coralie Poizat
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.